Compare the evidence

Sources, findings and their limits
Source and designPopulation or scopeFindingLimits
Official Tramalgesic label [1]Dog tramadol tabletsSeparates theoretical reduction of analgesia with mixed agonist/antagonists from CNS depression and other concerns.Clinical relevance of the metabolism interactions has not been studied in dogs.
Budsberg et al., 2018 — randomized blinded crossover trial [2]40 osteoarthritis dogs enrolled; 35 completedTramadol as administered in 10-day periods showed no clinical benefit; carprofen showed improvement.Chronic osteoarthritis findings do not establish postoperative efficacy or combination compatibility.
Donati et al., 2021 — systematic review and meta-analysis [3]26 postoperative randomized trials; 848 dogsRescue-analgesia RR versus placebo/no treatment: 0.47 (95% CI 0.26–0.85), moderate certainty for this comparison.Overall efficacy evidence was low or very low; endpoints and certainty differ across comparisons.

Which official source supports this tramadol overview?

Tramalgesic 50 mg Tablets for Dogs separates CNS and respiratory depression, seizure-threshold effects, metabolism and mixed-opioid combinations. These concerns have different mechanisms and evidence limits; they should be reviewed individually. [1]

What does the label say about tramadol with buprenorphine or butorphanol?

The label says combining tramadol with mixed agonist/antagonists such as buprenorphine or butorphanol is not advisable because analgesic effect may theoretically be reduced. It supplies no measured failure rate for these combinations. [1]

What is the concern with other medicines that cause sedation?

Concurrent CNS depressants may potentiate CNS and respiratory depression. This is separate from the theoretical reduction in analgesia with mixed-opioid combinations. Include premedication and other sedating medicines in the medication history. [1]

Are all metabolism-related tramadol interactions proven clinically in dogs?

No. After describing potential effects of CYP450 inhibitors and inducers, the label states that their clinical relevance has not been studied in dogs. That qualification belongs specifically to its metabolism discussion. [1]

Is tramadol evidence the same for osteoarthritis and postoperative pain in dogs?

No. A 2018 osteoarthritis trial found no clinical benefit from tramadol as administered, while a 2021 postoperative review reported reduced rescue-treatment requirements versus placebo or no treatment. Different pain settings and endpoints prevent a single universal efficacy conclusion. [2] [3]

Does this dog tablet label authorize the same plan in cats?

No. This dog tablet label establishes neither feline authorization nor a cat treatment schedule. A different species, formulation or route requires its own evidence and prescribing assessment. [1]

Evidence appraisal

The interaction label and clinical efficacy studies answer different questions. In a 2018 randomized, blinded, placebo-controlled crossover trial, Budsberg and colleagues enrolled 40 dogs with elbow or stifle osteoarthritis; 35 completed the study. Tramadol, as administered for 10-day treatment periods, produced no clinical benefit in the reported gait and owner-assessment endpoints, whereas carprofen showed improvement. This is evidence about that chronic osteoarthritis setting, not a trial of tramadol with buprenorphine or proof about every pain condition. [2]

Evidence differs by pain setting. Donati and colleagues’ 2021 systematic review included 26 randomized postoperative trials involving 848 dogs. For rescue-analgesia requirement versus placebo or no treatment, the reported relative risk was 0.47 (95% confidence interval 0.26–0.85), with moderate certainty for that comparison; certainty for several active-drug comparisons was lower. The authors judged overall efficacy evidence low or very low because of bias and imprecision. Rescue-treatment requirement after surgery is not the same endpoint as chronic osteoarthritis gait or function, and the review does not validate a tramadol–buprenorphine combination. [3]

The 2022 AAHA pain guidelines place pain assessment and a planned multimodal approach at the center of treatment. Multimodal does not mean that any two opioids are compatible. The Tramalgesic label separately identifies theoretical reduction of analgesia with mixed agonist/antagonists, additive CNS and respiratory depression, seizure-threshold effects and metabolism-related uncertainty. Each concern needs its own interpretation. [4] [1]

Clinical interpretation and follow-up

Define the outcome being assessed: pain behavior and function, or excessive depression. The AAHA pain guideline emphasizes pain recognition and owner observations, especially in chronic pain. An apparently quieter dog does not by itself establish adequate analgesia; the label's separate warnings support recording both domains. [4] [1]

Interpret the evidence with the indication, route, actual administration times and other sedatives. Osteoarthritis findings cannot determine a postoperative rescue plan, and the interaction label supplies no interchangeable opioid dose or switch interval. Pain reassessment and regimen compatibility are distinct tasks. [2] [1]

Questions for veterinary review

Editorial discussion checklist for your veterinarian:

  • Bring the full analgesic and sedative medication list to the veterinarian.
  • Keep theoretical analgesic antagonism separate from additive respiratory-depression concerns.
  • Request a veterinary pain assessment rather than adding or substituting an opioid based on a checker result.

Catalogue review status and evidence limits

The catalogue records contain verified direct evidence (dog): a species-scoped official-label statement, not necessarily a controlled interaction trial. The linked label PDF was also checked for publication.

A verified warning does not establish an individual animal's outcome, a patient-specific dose or independent clinical review. No matching rule does not prove safety.

Evidence sources

Citation scope: official labels support the interaction warnings; research and guidelines provide separately identified context. Each citation shows its document version or literature type and review scope. Catalogue identifiers may refer to earlier versions; this article uses the linked label PDF. Repeated labels are not independent studies. Source URLs and product authorizations may change.

  1. VMD: Tramalgesic 50 mg Tablets for Dogs — Summary of Product Characteristics

    Evidence type: Official product label. Revised December 2025. 4.8, interactions; 4.9, administration. Page 3. Source checked: . Open official VMD source

  2. Lack of effectiveness of tramadol hydrochloride for the treatment of pain and joint dysfunction in dogs with chronic osteoarthritis.

    Budsberg SC et al. J Am Vet Med Assoc. 2018;252(4):427-432. Evidence type: Primary study. Review scope: Abstract and bibliographic record. Source checked: . Open research source

  3. Efficacy of tramadol for postoperative pain management in dogs: systematic review and meta-analysis.

    Donati PA et al. Vet Anaesth Analg. 2021;48(3):283-296. Evidence type: Systematic review and meta-analysis. Review scope: Abstract and bibliographic record. Source checked: . Open research source

  4. 2022 AAHA Pain Management Guidelines for Dogs and Cats.

    Gruen ME et al. J Am Anim Hosp Assoc. 2022;58(2):55-76. Evidence type: Consensus guideline. Review scope: Abstract and bibliographic record. Source checked: . Open research source

Content responsibility: ZooDDI. For veterinary discussion, not diagnosis, prescribing or emergency care. No independent veterinary clinical review has been completed.

Check a complete medication regimen